Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yale University
With
National Alliance for Research on Schizophrenia and Depression
Donaghue Medical Research Foundation
Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a non-interactive placebo for 12 weeks.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of schizophrenia or schizoaffective disorder
Exclusion
Pregnant or lactating
Clareo Health | D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
